Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Microbicides 2002: an update.

Rowena Johnston1

  • 1American Foundation for AIDS Research, New York, New York 10005, USA. Rowena.Johnston@amfar.org

AIDS Patient Care and Stds
|October 25, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characterizing Symptoms and Identifying Biomarkers of Long COVID in People With and Without HIV: Protocol for a Remotely Conducted Prospective Observational Cohort Study.

JMIR research protocols·2023
Same author

Non-invasive plasma glycomic and metabolic biomarkers of post-treatment control of HIV.

Nature communications·2021
Same author

What Might Surviving Coronavirus Disease 2019 Look Like for People Living with HIV?

AIDS patient care and STDs·2020
Same author

Multi-stakeholder consensus on a target product profile for an HIV cure.

The lancet. HIV·2020
Same author

The first 6 months of HIV-SARS-CoV-2 coinfection: outcomes for 6947 individuals.

Current opinion in HIV and AIDS·2020
Same author

Engaging Cell and Gene Therapists in HIV Cure.

Human gene therapy·2020
Same journal

<i>Letter:</i> Limited Use of Proviral Sequencing in Adults with HIV Starting Long-Acting Injectable Cabotegravir-Rilpivirine.

AIDS patient care and STDs·2026
Same journal

Early Implementation of Doxycycline Postexposure Prophylaxis at an Infectious Diseases Clinic in the Southern United States.

AIDS patient care and STDs·2026
Same journal

Enhancing Pre-Exposure Prophylaxis Prescribing and Uptake Among Black Women in an Urban Sexually Transmitted Infections Clinic: A Quality Improvement Project.

AIDS patient care and STDs·2026
Same journal

People with HIV Continuing on Complex Regimens in the Era of Treatment Optimization: Characteristics and Outcomes.

AIDS patient care and STDs·2026
Same journal

HIV-Related Stigma Assessment Through an Integrated Digital Strategy in Routine Clinical Care.

AIDS patient care and STDs·2026
Same journal

Sexual Acquisition of HCV in Women Living with HIV: Biological Plausibility, Epidemiological Signals, and Implications for Enhanced Testing and Treatment Strategies.

AIDS patient care and STDs·2026
See all related articles

Developing an anti-Human Immunodeficiency Virus (HIV) microbicide is crucial for preventing sexual transmission, as an HIV vaccine is unlikely to fully avert infection. This summary covers advances in microbicide development discussed at the 2002 International Microbicides Conference.

Area of Science:

  • Microbiology and Virology
  • Public Health
  • Pharmaceutical Sciences

Background:

  • The development of an acquired immune deficiency syndrome (AIDS) vaccine is unlikely to fully prevent human immunodeficiency virus (HIV) infection.
  • Prevention strategies are increasingly focused on microbicides to reduce sexual HIV transmission.

Framework:

  • Microbicides, such as topical creams or gels, are applied before intercourse to decrease HIV transmission risk.
  • The 2002 International Microbicides Conference in Antwerp, Belgium, provided a platform to discuss the latest advancements in anti-HIV microbicide development.

Implementation:

  • The conference covered basic scientific research, clinical trial progress, and the social, political, and economic factors influencing microbicide development.
  • Key discussions included challenges and opportunities in bringing effective microbicides to market.

Related Experiment Videos

Implications:

  • Successful microbicide development could significantly impact global HIV/AIDS prevention efforts.
  • Continued research and collaboration are essential for the effective implementation of microbicide-based prevention strategies.